RNA, 3D Printing and Mass Data: Not a vision but a reality

Dr. Ingmar Hoerr, MBA
Supervisory Board Chairman of CureVac AG

Moderator: Dr. med. Helmut Laaff

January 28th 2019, 17.00 (s.t.)
Lecture Hall Otto Kraye Haus
Albertstrasse 25
Dr. Ingmar Hoerr, MBA, Supervisory Board Chairman of CureVac AG and its CEO till 2018, founded the biopharmaceutical company with colleagues in Tübingen in the year 2000. The initiative was based on a surprising discovery during his doctoral thesis. Contrary to the existing knowledge at that time, his experiments showed that mRNAs could be directly applied to tissues and after their cellular uptake were effectively translated into proteins. As an inventor of this mRNA technology Ingmar Hoerr built up with his team the company CureVac, which for the first time worldwide started to apply mRNAs in clinical trials in humans. As a German „Unicorn“ the company became the leader in the research and development of mRNA-based therapeutics. It has acquired over 400 million € capital since its foundation and has currently a value of over 1.7 billion €, steadily increasing with its first subsidiary in the US. Main investor of CureVac is Dietmar Hopps dievini Hopp BioTech holding GmbH & Co.

Ingmar Hoerr obtained his doctoral degree from the University of Tübingen and his MBA from the Donau University, Krems, Austria. He is a honorary senator of the University of Tübingen. He advises the European Commission as a member of the High Level Group of Innovators for the organization of the European Council for Innovation. He is also a Juror of the Founder Award Weconomy.

The seminar series “Academia meets Industry” aims at stimulating interdisciplinary discussions between university members and high profile managers from industry and public health organizations. It addresses the complex challenges in science, management, politics and society which are promoted by both university and industry in a concerted action. At these seminars the practical perspective of the guest speakers encounters the education and research priorities of the university and thus allows an unprecedented dialogue on chances and risks of current and future research developments in life sciences.